EUVIMEDEUVIMED entdecken
Crossref

Development of a novel manufacturing process for highly purified and stable immunoglobulin M with enhanced plasma utilization

Wen-Rong Xia, Bo-Guang Jiang, Yi Zhong, Wei Liu, Gui-Hong Li, Yang-Li Lu, Dong-Qiang Lin iD

Vox Sanguinis · 09.11.2026

DOI: 10.1111/vox.70414 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vox Sanguinis, online erschienen am 09.11.2026. Verfasst von Wen-Rong Xia und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, China. Die Arbeit nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Immunoglobulin M (IgM) is a promising therapeutic agent. However, its production is limited by high molecular weight, complex structure and poor stability. This study aimed to develop a novel manufacturing process for high‐purity, stable plasma‐derived IgM while improving plasma utilization. Materials and Methods The flow‐through fraction from first‐step anion‐exchange chromatography (Step 1 AEX) in an intravenous immunoglobulin manufacturing process was used as the starting material. Second‐step AEX (Step 2 AEX) and third‐step mixed‐mode chromatography (Step 3 MMC) were used to remove impurities, including prekallikrein activator (PKA), immunoglobulin G (IgG), immunoglobulin A (IgA) and α2‐macroglobulin. The elution conditions for Step 2 AEX were optimized to improve IgM recovery and purity. Four resins were evaluated for Step 3 MMC, and separation conditions were optimized to increase IgM purity and recovery. Finally, formulation studies were conducted to improve IgM stability. Results The optimized conditions were stepwise elution for Step 2 AEX (0.4 M followed by 1.0 M sodium acetate), Capto Core 400 resin for flow‐through‐mode Step 3 MMC and loading at pH 7.8, conductivity 15.0 mS/cm and protein concentration 1.0% ( w / v ). Key impurities IgA and PKA were reduced to 0.184 ± 0.011 mg/mL and below the limit of detection (90%). By optimizing plasma utilization, this process represents a promising platform for next‐generation immunoglobulin therapies.

Schlagwörter

Stichwörter der Autor:innen

human plasmaimmunoglobulin Mion exchangemixed‐mode chromatographypharmaceutical formulationprotein purification

Autor:innen und Institutionen

  • College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, China.
  • Research Institute, Grand Shuyang Life Sciences (Chengdu) Co., Ltd., Chengdu, China.

ORCID-Profile: Dong-Qiang Lin

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xia, W. R., Jiang, B. G., Zhong, Y., Liu, W., Li, G. H., Lu, Y. L., & Lin, D. Q. (2026). Development of a novel manufacturing process for highly purified and stable immunoglobulin M with enhanced plasma utilization. Vox Sanguinis. https://doi.org/10.1111/vox.70414

Vancouver

Xia WR, Jiang BG, Zhong Y, Liu W, Li GH, Lu YL, et al. Development of a novel manufacturing process for highly purified and stable immunoglobulin M with enhanced plasma utilization. Vox Sanguinis. 2026. doi:10.1111/vox.70414

BibTeX
@article{Xia2026,
  author = {Xia, Wen-Rong and Jiang, Bo-Guang and Zhong, Yi and Liu, Wei and Li, Gui-Hong and Lu, Yang-Li and Lin, Dong-Qiang},
  title = {Development of a novel manufacturing process for highly purified and stable immunoglobulin M with enhanced plasma utilization},
  journal = {Vox Sanguinis},
  year = {2026},
  doi = {10.1111/vox.70414}
}
Kostenlos starten →